FDA Approves Groundbreaking New Schizophrenia Drug Cobenfy
28.09.2024, 16:00
The U.S. Food and Drug Administration (FDA) has approved Cobenfy, a first-in-class antipsychotic medication for the treatment of schizophrenia, marking the first new pharmacological approach for the disorder in over 30 years. This revolutionary drug, developed by Bristol Myers Squibb, promises to...